EUVIMEDEUVIMED entdecken
Crossref

Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer

Yan Chen, Endong Wu, Yifeng Ma, Guangli Shi

Clinical Laboratory · 2025

DOI: 10.7754/clin.lab.2024.240432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2025. Verfasst von Yan Chen und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Biomarkers, Tumor.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) have been widely used in the treatment of lung cancer, and they significantly improve the survival rate of patients. However, the benefit rate of ICIs immunotherapy for lung cancer patients is only 15 - 40%. It is necessary to find effective and reliable biomarkers for evaluating the curative effect to achieve accurate immunotherapy for lung cancer. Therefore, the objective of this study was to analyze the value of response evaluation through detecting serum neuron-specific enolase (NSE), pro-gastrin-releasing peptide (pro-GRP), cytokeratin 19 fragment (Cyfra21-1), squamous cell carcinoma antigen (SCC), and carcinoembryonic antigen (CEA) in the lung cancer patients treated with ICIs. METHODS: The levels of serum NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the lung cancer patients of pre- and post-immunotherapy with ICIs were detected by flow fluorescence method. RESULTS: The serum levels of NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the patients with partial remission were decreased after ICIs immunotherapy of 2 cycles, and the difference was statistically significant (p 0.05). The sensitivities of NSE, pro-GRP, Cyfra21-1, SCC, and CEA in evaluating the efficacy of immunotherapy were 92.3%, 84.6%, 95.4%, 96.7%, and 81.3%. CONCLUSIONS: The changed levels of serum NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the lung cancer patients in pre- and post-immunotherapy with ICIs were related to the therapeutic effect and may be used for the response evaluation. The SCLC patients should choose serum NSE, pro-GRP, and CEA for the response evaluation of ICIs immunotherapy, and the NSCLC patients should choose serum Cyfra21-1, SCC, and CEA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmune Checkpoint InhibitorsBiomarkers, TumorHumansMaleMiddle AgedFemaleAntigens, NeoplasmKeratin-19AgedPhosphopyruvate HydrataseCarcinoembryonic AntigenSerpinsTreatment OutcomeGastrin-Releasing PeptideAdultImmunotherapy

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorAntigens, NeoplasmKeratin-19Phosphopyruvate Hydrataseantigen CYFRA21.1Carcinoembryonic Antigensquamous cell carcinoma-related antigenSerpinsGastrin-Releasing Peptide

Zitieren

APA

Chen, Y., Wu, E., Ma, Y., & Shi, G. (2025). Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2024.240432

Vancouver

Chen Y, Wu E, Ma Y, Shi G. Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer. Clinical Laboratory. 2025. doi:10.7754/clin.lab.2024.240432

BibTeX
@article{Chen2025,
  author = {Chen, Yan and Wu, Endong and Ma, Yifeng and Shi, Guangli},
  title = {Value of Serum Markers in Evaluating the Curative Effect of Immune Checkpoint Inhibitors for Lung Cancer},
  journal = {Clinical Laboratory},
  year = {2025},
  doi = {10.7754/clin.lab.2024.240432}
}
Kostenlos starten →